Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.

[1]  J. Lawson,et al.  Design, synthesis and optimization of novel Alk5 (activin-like kinase 5) inhibitors. , 2016, Bioorganic & medicinal chemistry letters.

[2]  S. Estrem,et al.  Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway , 2015, Drug design, development and therapy.

[3]  M. Abdullah,et al.  Inhibition of transforming growth factor-β via the activin receptor-like kinase-5 inhibitor attenuates pulmonary fibrosis. , 2015, Molecular medicine reports.

[4]  Jeong-Seok Nam,et al.  EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling , 2014, Cellular and Molecular Life Sciences.

[5]  K. S. Rao,et al.  Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent. , 2014, Journal of medicinal chemistry.

[6]  I. Fabregat,et al.  TGF-beta signaling in cancer treatment. , 2014, Current pharmaceutical design.

[7]  E. Terpos,et al.  Activin receptor antagonists for cancer-related anemia and bone disease , 2013, Expert opinion on investigational drugs.

[8]  R. Akhurst,et al.  Complexities of TGF-β Targeted Cancer Therapy , 2012, International journal of biological sciences.

[9]  Mostofa A Hena,et al.  Discovery of a series of 2-(1H-pyrazol-1-yl)pyridines as ALK5 inhibitors with potential utility in the prevention of dermal scarring. , 2012, Bioorganic & medicinal chemistry letters.

[10]  L. Ling,et al.  Tgf-beta type I receptor (Alk5) kinase inhibitors in oncology. , 2011, Current pharmaceutical biotechnology.

[11]  J. Render,et al.  An Activin Receptor-Like Kinase 5 Inhibitor Reduces Collagen Deposition in a Rat Dermal Incision Wound Healing Model , 2011, Plastic and reconstructive surgery.

[12]  M. Anderton,et al.  Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors , 2011, Toxicologic pathology.

[13]  David J. Nesbitt,et al.  Definition of the hydrogen bond (IUPAC Recommendations 2011) , 2011 .

[14]  R. Obach.  Predicting clearance in humans from in vitro data. , 2011, Current topics in medicinal chemistry.

[15]  F. Gellibert,et al.  Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[16]  R. Campbell,et al.  Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. , 2008, Journal of medicinal chemistry.

[17]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[18]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[19]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[20]  C. Chuaqui,et al.  Successful shape-Based virtual screening: The discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI) , 2003 .

[21]  A. Reith,et al.  SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. , 2002, Molecular pharmacology.

[22]  D E McRee,et al.  XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. , 1999, Journal of structural biology.

[23]  A. Vagin,et al.  MOLREP: an Automated Program for Molecular Replacement , 1997 .

[24]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[25]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[26]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.